Martin Latterich - 17 Feb 2022 Form 4 Insider Report for Histogen Inc.

Reporting relationship: SVP, Technical Operations
Issuer ticker: N/A
Reported as of: 17 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Feb 2022, 17:18:41 UTC
Prior SEC filing: 10 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Susan A. Knudson as attorney-in-fact for Martin Latterich

Key filing fact

Martin Latterich filed Form 4 for Histogen Inc. on 22 Feb 2022.

Key facts

This page summarizes Martin Latterich's Form 4 filing for Histogen Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Feb 2022, 17:18.

Change

Previous filing in this sequence was filed on 10 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HSTO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +134,900
Change %
Price: $0.000000
Shares after: 134,900
Date: 17 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 134,900
Exercise price: $0.2400
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4 of the shares subject to the option vest one year after the date of grant, on 2/17/2023, and the remaining 1/36 of the shares vest on a monthly basis thereafter.